Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Research & Development (2016 - 2025)

Outlook Therapeutics has reported Research & Development over the past 8 years, most recently at $3.6 million for Q4 2025.

  • Quarterly Research & Development fell 62.38% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.2 million through Dec 2025, down 25.46% year-over-year, with the annual reading at $27.2 million for FY2025, 34.92% down from the prior year.
  • Research & Development was $3.6 million for Q4 2025 at Outlook Therapeutics, down from $6.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $9.7 million in Q4 2024 and troughed at $3.6 million in Q4 2025.